NL-OMON38964已完成3 期
A Phase III, randomised trial of adding nitroglycerin to first line chemotherapy for advanced non-small cell lung cancer (NITRO TRIAL, NVALT-21 study) - NVALT21 NITRO TRIA
Stichting NVALT studies0 个研究点目标入组 150 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Stage III or IV non-small cell lung carcinoma. Measurable disease is not required.
- •2. ECOG performance status of 0, 1 or 2.
- •3. Radiotherapy completed at least 1 week before randomisation.
- •4. At least 18 years of age.
- •5. Adequate contraception for 30 days prior to drug administration for females of childbearing potential.
排除标准
- •1. Untreated brain or meningeal metastases.
- •2. Life expectancy less than 3 months.
- •3. Any prior systemic therapy for advanced NSCLC. Adjuvant chemotherapy for NSCLC completed more than 12 months before randomisation is allowed.
- •4. On nitrates, dihydroergotamine or phosphodiesterase inhibitors.
- •5. Uncontrolled cardiovascular disease.
- •6. Pregnancy, lactation.
研究者
相似试验
进行中（未招募）
不适用
A trial of adding nitroglycerin tochemotherapy for advanced lung cancerEUCTR2013-002050-78-NLVALT500
已完成
3 期
A Phase III, randomised trial of adding nitroglycerin to first line chemotherapy for advanced non-small cell lung cancerACTRN12608000588392niversity of Sydney372
进行中（未招募）
1 期
A randomised Phase III trial to evaluate the efficacy of chemoimmunotherapy with the monoclonal antibody Campath-1H (Alemtuzumab) given in combination with 2-weekly CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) versus 2-weekly CHOP alone in elderly patients with previously untreated systemic T- cell Lymphoma Short Title: A-CHOP-14 (elderly) - A-CHOP-14 (elderly)Primary therapy of patients with Alk-negative T-NHL in patients aged 61 - 80 yearsICD classification codes : ICD-O 9702/39717/39716/39708/39705/39714/3MedDRA version: 9.1Level: LLTClassification code 10002464Term: Angiomimmunoblastic (AILD, LgX (Kiel Classification)MedDRA version: 9.1Level: LLTClassification code 10025632Term: Malignant lymphomaEUCTR2007-000821-23-BEniversity Medicine Goettingen274
进行中（未招募）
1 期
A randomised Phase III trial to evaluate the efficacy of chemoimmunotherapy with the monoclonal antibody Campath-1H (Alemtuzumab) given in combination with 2-weekly CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) versus 2-weekly CHOP alone in elderly patients with previously untreated systemic T- cell Lymphoma Short Title: A-CHOP-14 (elderly) - A-CHOP-14 (elderly)Primary therapy of patients with Alk-negative T-NHL in patients aged 61 - 80 yearsICD classification codes : ICD-O 9702/39717/39716/39708/39705/39714/3MedDRA version: 9.1Level: LLTClassification code 10002464Term: Angiomimmunoblastic (AILD, LgX (Kiel Classification)MedDRA version: 9.1Level: LLTClassification code 10025632Term: Malignant lymphomaEUCTR2007-000821-23-ATniversity Medicine Goettingen276
进行中（未招募）
1 期
A randomised Phase III trial to evaluate the efficacy of chemoimmunotherapy with the monoclonal antibody Campath-1H (Alemtuzumab) given in combination with 2-weekly CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) versus 2-weekly CHOP alone in elderly patients with previously untreated systemic T- cell Lymphoma Short Title: A-CHOP-14 (elderly) - A-CHOP-14 (elderly)Primary therapy of patients with Alk-negative T-NHL in patients aged 61 - 80 years ICD classification codes : ICD-O 9702/39717/39716/39708/39705/39714/3MedDRA version: 9.1 Level: LLT Classification code 10002464 Term: Angiomimmunoblastic (AILD, LgX (Kiel Classification)MedDRA version: 9.1 Level: LLT Classification code 10025632 Term: Malignant lymphomaEUCTR2007-000821-23-FRniversity Medicine Goettingen274